Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset

Overview

Journal Am J Public Health

Specialty Public Health

Date 1998 Sep 16

PMID 9736873

Citations 546

Authors

R Brookmeyer

S Gray

C Kawas

Affiliations

Soon will be listed here.

Abstract

Objectives: The goal of this study was to project the future prevalence and incidence of Alzheimer's disease in the United States and the potential impact of interventions to delay disease onset.

Methods: The numbers of individuals in the United States with Alzheimer's disease and the numbers of newly diagnosed cases that can be expected over the next 50 years were estimated from a model that used age-specific incidence rates summarized from several epidemiological studies, US mortality rates, and US Bureau of the Census projections.

Results: in 1997, the prevalence of Alzheimer's disease in the United States was 2.32 million (range: 1.09 to 4.58 million); of these individuals, 68% were female. It is projected that the prevalence will nearly quadruple in the next 50 years, by which time approximately 1 in 45 Americans will be afflicted with the disease. Currently, the annual number of new incident cases in 360,000. If interventions could delay onset of the disease by 2 years, after 50 years there would be nearly 2 million fewer cases than projected; if onset could be delayed by 1 year, there would be nearly 800,000 fewer prevalent cases.

Conclusions: As the US population ages, Alzheimer's disease will become an enormous public health problem. interventions that could delay disease onset even modestly would have a major public health impact.

Citing Articles

Dynamic lifetime risk prediction of Alzheimer's disease with longitudinal cognitive assessment measurements.

Ding H, Ye Z, Paschalidis A, Bennett D, Au R, Lin H Alzheimers Dement. 2025; 21(3):e70055.

PMID: 40042504 PMC: 11881628. DOI: 10.1002/alz.70055.

Network Biomarkers of Alzheimer's Disease Risk Derived from Joint Volume and Texture Covariance Patterns in Mouse Models.

Bridgeford E, Chung J, Anderson R, Mahzarnia A, Stout J, Moon H bioRxiv. 2025; .

PMID: 39975084 PMC: 11838544. DOI: 10.1101/2025.02.05.636582.

Ellagic Acid: A Green Multi-Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer's Disease.

Alfei S, Zuccari G Int J Mol Sci. 2025; 26(2).

PMID: 39859559 PMC: 11766176. DOI: 10.3390/ijms26020844.

Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease.

Carles A, Freyssin A, Guehairia S, Reguero T, Vignes M, Hirbec H Alzheimers Res Ther. 2025; 17(1):7.

PMID: 39762936 PMC: 11702188. DOI: 10.1186/s13195-024-01648-9.

Deep learning analysis of fMRI data for predicting Alzheimer's Disease: A focus on convolutional neural networks and model interpretability.

Zhou X, Kedia S, Meng R, Gerstein M PLoS One. 2024; 19(12):e0312848.

PMID: 39630834 PMC: 11616848. DOI: 10.1371/journal.pone.0312848.

References

Rice D, Fox P, Max W, Webber P, Lindeman D, Hauck W . The economic burden of Alzheimer's disease care. Health Aff (Millwood). 1993; 12(2):164-76. DOI: 10.1377/hlthaff.12.2.164. View

Small G, Rabins P, BARRY P, Buckholtz N, DeKosky S, Ferris S . Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997; 278(16):1363-71. View

Paganini-Hill A, Henderson V . Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994; 140(3):256-61. DOI: 10.1093/oxfordjournals.aje.a117244. View

Brenner D, Kukull W, Stergachis A, van Belle G, Bowen J, McCormick W . Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994; 140(3):262-7. DOI: 10.1093/oxfordjournals.aje.a117245. View

Ernst R, Hay J . The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994; 84(8):1261-4. PMC: 1615456. DOI: 10.2105/ajph.84.8.1261. View

Henderson V, Paganini-Hill A, Emanuel C, Dunn M, Buckwalter J . Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994; 51(9):896-900. DOI: 10.1001/archneur.1994.00540210068014. View

Hebert L, Scherr P, Beckett L, Albert M, Pilgrim D, Chown M . Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995; 273(17):1354-9. View

Letenneur L, Commenges D, Dartigues J, Barberger-Gateau P . Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. Int J Epidemiol. 1994; 23(6):1256-61. DOI: 10.1093/ije/23.6.1256. View

Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K . Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995; 45(6):1161-8. DOI: 10.1212/wnl.45.6.1161. View

10.

Andersen K, Launer L, Ott A, Hoes A, Breteler M, Hofman A . Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology. 1995; 45(8):1441-5. DOI: 10.1212/wnl.45.8.1441. View

11.

Cobb J, Wolf P, Au R, White R, DAgostino R . The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology. 1995; 45(9):1707-12. DOI: 10.1212/wnl.45.9.1707. View

12.

Corrada M, Brookmeyer R, Kawas C . Sources of variability in prevalence rates of Alzheimer's disease. Int J Epidemiol. 1995; 24(5):1000-5. DOI: 10.1093/ije/24.5.1000. View

13.

Breitner J, Welsh K, Helms M, Gaskell P, Gau B, Roses A . Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995; 16(4):523-30. DOI: 10.1016/0197-4580(95)00049-k. View

14.

Lautenschlager N, Cupples L, Rao V, Auerbach S, Becker R, Burke J . Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old?. Neurology. 1996; 46(3):641-50. DOI: 10.1212/wnl.46.3.641. View

15.

van Duijn C . Epidemiology of the dementias: recent developments and new approaches. J Neurol Neurosurg Psychiatry. 1996; 60(5):478-88. PMC: 486358. DOI: 10.1136/jnnp.60.5.478. View

16.

Tang M, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B . Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996; 348(9025):429-32. DOI: 10.1016/S0140-6736(96)03356-9. View

17.

McGeer P, Schulzer M, McGeer E . Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996; 47(2):425-32. DOI: 10.1212/wnl.47.2.425. View

18.

White L, Petrovitch H, Ross G, Masaki K, Abbott R, Teng E . Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. JAMA. 1996; 276(12):955-60. View

19.

Martin G, Kukull W . Do cultural differences affect Alzheimer disease?. JAMA. 1996; 276(12):993-5. View

20.

Fourrier A, Letenneur L, Begaud B, Dartigues J . Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol. 1996; 49(10):1201. DOI: 10.1016/0895-4356(96)00202-8. View